NFKB1 and posterior cortical atrophy: AsA treatment led to a dose-dependent decrease in NF-κB activity to 76.53 ± 3.37%, 57.20 ± 3.78% (p < 0.01) and 35.42 ± 3.37% (p < 0.001) as shown in Figure 2D, indicating that AsA mediated the inhibition of NF-κB in PCa cells.